文献速递骨软组织肉瘤与黑色素瘤

将ctDNA纳入皮肤黑色素瘤诊疗:国际专家调查

Translating ctDNA into cutaneous melanoma care: An international expert survey.
PubMed 文献 · Eur J Cancer · 2026-03-19

该调查面向黑色素瘤世界学会研究组116名成员,评估ctDNA在预设临床场景中的价值。专家认为ctDNA在微小残留病检测、复发监测和IV期黑色素瘤中价值最高,在早期阶段效用有限,并视其为优于S100和LDH的早期复发检测工具。主要障碍包括需要前瞻性试验、标准化指南和报销政策。

要点

  • ctDNA在微小残留病检测、复发监测和IV期黑色素瘤中价值最高。
  • 专家认为ctDNA在早期复发检测和识别进展方面优于S100和LDH。
  • 中枢神经系统病灶不推荐血ctDNA,66%认为脑脊液ctDNA有价值。

核心结论

  • 关键意见领袖认为ctDNA在特定黑色素瘤场景中是有价值的辅助工具。
  • 前瞻性研究验证、指南制定和报销框架是更广泛临床实施的必要条件。

研究设计与样本

  • 基于网络的调查,纳入黑色素瘤世界学会研究组的116名成员。
  • 问卷包括18个关于ctDNA使用的一般问题和5个含去标识患者数据及回顾性ctDNA结果的临床案例。

主要发现

  • ctDNA在微小残留病检测中平均评分为3.63,复发监测为3.85,IV期黑色素瘤为3.82,早期阶段效用有限。
  • 80%的参与者同意ctDNA与影像学缓解相关,82%支持将其纳入常规随访。
  • 在高肿瘤负荷紧急情况下,若组织分析待定,82.8%会根据ctDNA启动BRAFi/MEKi治疗;若组织不可用,93.9%会启动。
  • 对于中枢神经系统病灶,62%不支持血ctDNA,66%认为脑脊液ctDNA有价值。
  • 主要障碍包括需要前瞻性试验(85%)、标准化指南(83%)和报销政策(82%)。

关键数值与推荐

  • 专家偏好使用小到中型靶向panel和短周转时间的务实方法。

临床怎么用

  • 在微小残留病检测、复发监测和IV期黑色素瘤中可考虑使用ctDNA。
  • 在高肿瘤负荷紧急情况下,若组织分析待定或不可用,可根据ctDNA启动BRAFi/MEKi治疗。
  • 中枢神经系统病灶优先考虑脑脊液ctDNA而非血ctDNA。
  • 采用小到中型靶向panel和短周转时间的方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Circulating tumor DNA (ctDNA) is a promising biomarker in melanoma, with higher sensitivity for tumor burden detection than conventional diagnostics. While well established in research, clinical routine implementation remains pending. Key global questions concern optimal clinical applications and barriers to adoption. METHODS: A web-based survey of 116 members of the Melanoma World Society Study Group assessed international expert opinions on ctDNA utility across predefined clinical scenarios. The questionnaire included 18 general questions on ctDNA use and 5 clinical vignettes with de-identified patient data and retrospectively obtained ctDNA results. RESULTS: ctDNA was rated most valuable for detecting minimal residual disease (mean score 3.63), surveillance of recurrent disease (3.85), and stage IV melanoma (3.82), with limited utility in early stages. Experts considered ctDNA superior to S100 and LDH for early relapse detection and identifying progressive disease. Most participants (80%) agreed that ctDNA correlates with radiographic response, and 82% favored its integration into routine follow-ups. In urgent high-tumor-burden settings, 82.8% would initiate BRAFi/MEKi therapy based on ctDNA if tissue analysis was pending, and 93.9% if unavailable. For central nervous system lesions, 62% did not support blood ctDNA, while 66% considered cerebrospinal fluid valuable. Pragmatic approaches with small to mid-size targeted panels and short turnaround times were preferred. Major barriers included the need for prospective trials (85%), standardized guidelines (83%), and reimbursement policies (82%). CONCLUSION: Key opinion leaders regarded ctDNA as a valuable adjunct selected melanoma scenarios. Validation through prospective studies, guideline development, and reimbursement frameworks are essential for broader clinical implementation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Geidel G, Fekade N, Raabe K, et al. Translating ctDNA into cutaneous melanoma care: An international expert survey. Eur J Cancer. 2026. PMID: 41932032. doi:10.1016/j.ejca.2026.116676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。